<DOC>
	<DOCNO>NCT00596258</DOCNO>
	<brief_summary>A-007 investigational therapy may effective treatment pre-cancerous cervical dysplasia ( abnormal cell growth ) . The purpose study evaluate safety efficacy A-007 , use treat high-grade cervical dysplasia .</brief_summary>
	<brief_title>A Two-Stage Phase 2 Study Of A-007 Topical Gel High-Grade Squamous Intraepithelial Lesions ( HSIL )</brief_title>
	<detailed_description>This non-randomized , two-stage phase II study pathological response rate primary objective . Following biopsy confirmation CIN 2/3 within last 12 week , woman treat gel apply cervix via intravaginal applicator . Patients apply gel daily 14 consecutive day 28-day cycle 2 cycle . Women return clinic safety assessment , colposcopy , cytology , virologic immunologic testing ( see schedule event attachment TG-003.01 visit interval ) . Following two cycle treatment A-007 , treat physician perform LEEP month 4 visit . The investigator responsible ensure LEEP conduct accord procedure guideline institution .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Uterine Cervical Dysplasia</mesh_term>
	<mesh_term>Squamous Intraepithelial Lesions Cervix</mesh_term>
	<criteria>18 year age older The patient authorize representative must sign date Ethical Review Boardapproved inform consent document . All aspect protocol must explain write informed consent obtain . Patients must histologic proof CIN 2/3 disease document within last 12 week . If patient enrol use prior local biopsy , local slide pathology report must send central laboratory . Patient may enrol study base local laboratory result CIN 2/3 discontinue central laboratory result differ . Cervical swab must test positive high risk HPV ( Hybrid Capture 2 ) . If patient test negative high risk HPV proof CIN 2/3 , patient retested one additional time highrisk HPV . Patients must Hgb ≥ 9 g/dl , peripheral WBC ≥ 3000 mm3 platelet count ≥100,000 mm3 . Normal hepatic renal function AST ALT &lt; 2.5 x ULN creatinine &lt; 1.5 x ULN , respectively . Females childbearing potential must use one follow birth control method study ( performance LEEP month 4 ) : oral , implantable , injectable contraceptive ; abstinence ( celibacy ) . Contraceptive sponge , IUD , vaginal contraceptive ring , spermacides , sponge , condom , partner 's vasectomy acceptable method birth control . Patients CIN 1 invasive squamous cell carcinoma ( SCC ) . CIN appear involve endocervix , assess colposcopically CIN amenable adequate colposcopic followup evaluation , i.e . unsatisfactory colposcopy . CIN 3 involve two cervical quadrant colposcopy . Patients treat cervical SIL within past year . Patients LEEP perform past 12 month Patients malignancy ( except nonmelanoma skin ) within past 5 year . Patients chronic , active infection ( include HIV ) HPV . Patients know clinically relevant immunological deficiency . Concurrent treatment cytotoxic , radiation , immunostimulative therapy , systemic corticosteroid dose &gt; 5 mg/d prednisone ( equivalent ) . Participation another investigational medication trial concurrently within 30 day , prior administration prophylactic HPV vaccine participation HPV vaccine trial . Treatment within last 30 day medication receive regulatory approval time study entry . Concomitant use topical vaginal medication . Significant acute chronic medical psychiatric illness , judgment Investigator , could compromise subject safety , limit subject 's ability complete study , and/or compromise objective study . History allergy hypersensitivity cosmetic , toiletry , topical dermatologic product . Pregnant lactating female nurse consent cease nursing . Investigators , site personnel directly affiliate study , immediate family . Immediate family define spouse , parent , child sibling , whether biological legally adopt . Patients know menstrual irregularity resolve cycle hormonal contraception .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Cervical Intraepithelial Neoplasia ( CIN )</keyword>
	<keyword>High-grade Cervical Intraepithelial Neoplasia</keyword>
	<keyword>High-grade Squamous Intraepithelial Lesions ( HSIL )</keyword>
	<keyword>Human Papilloma Virus ( HPV )</keyword>
	<keyword>High-Grade Cervical Intraepithelial Lesions ( CIN 2/3 )</keyword>
</DOC>